We’re proud of our highly interdisciplinary team and their incredible accomplishments in developing Ansa’s innovative technology.
Jason T. Gammack
Chief Executive Officer
Jason Gammack brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of building and scaling high-impact biotechnology businesses. Prior to joining Ansa, he co-founded and served as chief executive officer of Resolve Biosciences, where he helped launch a groundbreaking, highly multiplexed, multi-analyte spatial analysis platform. Previously, Mr. Gammack was chief commercial officer at Inscripta, overseeing global sales, marketing, business development and customer support for the company’s CRISPR-enabled digital genome engineering platform. Mr. Gammack has also held senior leadership roles at QIAGEN, Ingenuity Systems, Sigma-Aldrich, Invitrogen/Life Technologies, Affymetrix, and Promega Corp.
Geoff Hamilton
Chief Financial Officer and Chief Business Officer
Geoff Hamilton has more than 25 years of executive leadership experience across the life sciences and medical device sectors. He co-founded and served as chief executive officer of Stemson Therapeutics, a cell therapy company focused on developing curative treatments for hair loss. Before that, he held senior leadership roles at Illumina, Life Technologies, and Stryker, where he led financial planning, commercial strategy, strategic partnerships, product development, and global product launches supporting multiple high-growth business segments.
Dan Lin-Arlow, PhD
Chief Scientific Officer and co-founder
Dan Lin-Arlow is a scientist-entrepreneur with deep expertise in synthetic biology and biophysics. Motivated by firsthand challenges in obtaining DNA constructs for metabolic engineering in graduate school, he is deeply committed to providing scientists with the DNA constructs they need for their research. As Ansa’s founding CEO, Dr. Lin-Arlow grew the company from two employees in 2018 to more than 70 by 2024, raising more than $130 million in venture capital and grant funding to support technology development and commercialization. He transitioned to the role of Chief Scientific Officer in 2024, where he leads the development of new applications of the company’s technologies. Dr. Lin-Arlow is a co-inventor of 9 patent families and has co-authored scientific publications in Nature, Science, Cell, PNAS, and Nature Biotechnology that have been cited more than 8,500 times in aggregate.
Sebastian Palluk, PhD
Chief Technology Officer and co-founder
Dr. Sebastian Palluk is co-founder and CTO of Ansa Biotechnologies, and co-inventor of the company’s core technology with Dr. Lin-Arlow in Jay Keasling’s laboratory at Lawrence Berkeley National Laboratory and the Joint BioEnergy Institute. At Ansa, Dr. Palluk has built a highly interdisciplinary R&D team, which has developed proprietary enzymatic DNA synthesis methods, reagents, and custom-built instruments that enabled the company to set the world record for the longest oligonucleotide ever synthesized at 1,005 bases. Dr. Palluk is a co-inventor on 11 patent families related to enzymatic DNA synthesis.
Dave Bullis
Vice President, Strategic Marketing
Dave Bullis brings more than 25 years of experience across research, product management, and commercial leadership in the life sciences. At Ansa, he has played a central role in building the company’s go-to-market engine, launching its early access programs and first commercial products, establishing core digital and analytics infrastructure, and supporting key strategic partnerships. Previously, he held senior commercial and product leadership roles at Resolve Biosciences, Geneyx, QIAGEN, Illumina, Viridos (formerly Synthetic Genomics), and Syngenta. Throughout his career, Mr. Bullis has led the commercialization of innovative platforms, driven significant revenue growth, and helped bring complex scientific technologies successfully to market.
Scott Fay
Senior Vice President, Informatics
Scott Fay leads the design, development, and support of software systems that power Ansa’s enzymatic DNA synthesis platform. Since joining the company in 2022, he has overseen the development of Ansa’s manufacturing execution system, encompassing LIMS, work order orchestration, quality control, biosecurity screening, sample packaging management, and integrated manufacturing and R&D analytics. Prior to Ansa, Dr. Fay served as vice president of informatics at Phylagen and spent seven years at Invitae as a bioinformatics team lead and research scientist.
Evan King
Vice President, Sales
Evan King brings more than 30 years of experience in commercial and operations leadership roles in the pharmaceutical and life sciences industries. Prior to joining Ansa, he served as the vice president of strategic accounts for SomaLogic, where he led commercial operations and helped build and expand high-value partnerships. Earlier in his career, Mr. King was the chief operating officer at the Colorado Prevention Center, a non-profit clinical research and community health organization, and held senior project management roles at Allos Therapeutics and Gilead Sciences.
Nick Hurt, PhD, JD
Vice President, Legal
Nick Hurt brings more than 15 years of experience as a life sciences intellectual property attorney. At Ansa, he leads the company’s legal and intellectual property strategy. Previously, Dr. Hurt practiced at Goodwin and at Fenwick & West, advising biotechnology and life science companies on patent strategy, intellectual property portfolio development, and complex transactions.
John Trust
Vice President, Finance
John Trust has more than a decade of experience in financial planning and analysis in the life sciences sector. Prior to joining Ansa, he served as director of FP&A at Freenome, a company focused on early cancer detection. Previously, he held finance leadership roles at Tandem Diabetes Care and Illumina.
Matthias Arenskötter, PhD
Chief Operating Officer
Dr. Matthias Arenskötter brings a proven track record of optimizing advanced manufacturing systems for high-growth DNA synthesis and life sciences organizations. He spent more than 19 years at GeneArt, Life Technologies, and Thermo Fisher Scientific, where he held senior roles across manufacturing and manufacturing engineering for global operations. During his tenure, he built and scaled gene synthesis manufacturing operations for the US market and led the rapid expansion of qPCR assay production during the COVID-19 pandemic. He also helped scale the company’s digital manufacturing execution system infrastructure and led operations for numerous new product implementations.
Our Executive Team
Investors
